

Communication to HealthCare Professionals

Date: 15th December 2021

Mitomycine Substipharm 20 mg: Use of a single-use filtration device to avoid the risk of particles injection reactions

Information for consultant urologists

Dear Healthcare Professionals,

In accordance with the Medicine Authority, Substipharm, as Marketing Authorization Holder, wishes to inform you of the following measures:

- Some vials of Mitomycine Substipharm 20 mg may contain subvisible particles above the current specifications after reconstitution. This issue was identified during stability studies.
- No proven risk has been identified in relation to the administration of large amounts of sub-visible particles. Nevertheless, as precautionary measure, we implement a filtration measure before each administration. Therefore, we ask you to use single-use filter after reconstitution and whatever the route of administration. Full filtration instructions are provided in **Appendix 1**.
- From now on, a single-use filtration device Millex® HV (0.45 µm/PVDF) - Syringe Filter (picture below) will be included in each delivery of Mitomycine Substipharm 20 mg.
- Filtration does not alter the amount of the active ingredient mitomycin in the solution, nor does it reduce in the effectiveness of the medicine.



Background

Out of specification results for subvisible particles were observed during ongoing stability studies for the batches which were not distributed in Malta

Reminder of Therapeutic Indications:

- Mitomycin is administered intravenously for the treatment of gastric carcinoma, pancreatic carcinoma, colorectal carcinoma, metastatic breast cancers.
- Mitomycin is administered by intravesical use for relapse prevention with superficial urinary bladder carcinoma after transurethral resection.

Obtaining extra filters:

If you have *Mitomycine Substipharm 20 mg powder for solution for injection/infusion or intravesical use* in stock, please contact our representative in Malta for the filtration device:

EJ Busuttil Ltd; Busuttil Buildings

Triq I-Ghadam, Central Business District Zone 1 ; Birkirkara CBD 1060

Tel: 00356 21447184

Email : rp@ejbusuttil.com and info@ejbusuttil.com

Reporting of side effects:

Healthcare professionals are advised to report any side effects, including any possible side effects not listed in the product information. Report Forms can be downloaded from

www.medicinesauthority.gov.mt/adrportal and sent to **ADR reporting/ Post-Licensing Directorate**


Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN

3000, Malta, or sent by email to: Postlicensing.medicinesauthority@gov.mt

Medical information enquiries:

If you have any questions or require further information about *Mitomycine Substipharm 20 mg powder for solution for injection/infusion or intravesical use*, you can contact rp@ejbuuttil.com.


Best Regards,



Marine CONTRERAS

Qualified Person Deputy

Substipharm



GILBERT CAUCHI B.Pharm (Hons) M.Sc.
Responsible Person for Regulatory Affairs
and Pharmacovigilance
E.J. Busuttil Ltd

Gilbert Cauchi B.Pharm (Hons) M.Sc.





Responsible Person





EJ Busuttil Ltd, Busuttil Buildings, Triq I-Ghadam, Central Business District Zone 1, Birkirkara

Appendix 1: instruction regarding the reconstitution and filtration of *Mitomycine Substipharm 20mg*

Preliminary instructions:

- To ensure sterility do not use the package if the package is damaged
- Do not use this filter as an in-line filter for intravenous fluid administration; it is not designed for long-term continuous use.
- Do not use with syringes smaller than 10 cc because pressures in excess of the maximum pressure rating may be reached, potentially causing damaged to the filter unit and/or personal injury.

<p>1)</p> 	<p>1) Fill syringe with water for injection or NaCl 0.9 %</p>
<p>2)</p> 	<p>2) For intravenous injection: Reconstitute with 50ml of water for injection or NaCl 0.9%, the lyophilizate of <i>Mitomycine Substipharm 20 mg</i> to obtain the desired concentration of 0.4 mg/mL.</p> <p>For intravesical administration: Reconstitute with 20ml of water for injection or NaCl 0.9%, the lyophilizate of <i>Mitomycine Substipharm 20 mg</i> to obtain the desired concentration of 1 mg/mL.</p>
<p>3)</p> 	<p>3) Agitate the vial until complete dissolution for 2 minutes at least</p>
<p>4)</p> 	<p>4) Fill the syringe with the solution of <i>Mitomycine Substipharm 20 mg</i></p>

<p>5)</p> 	<p>5) Aseptically remove filter cover from package</p>
<p>6)</p> 	<p>6) Attach syringe to filter unit and remove assembly from package. Attach needle to Luer-slip outlet if necessary.</p>
<p>7)</p> 	<p>7) Hold syringe with filter (and needle if attached) pointing up and top off by pushing a few drops through. Do not contaminate underside of filter unit with fingers.</p>
<p>8)</p> 	<p>8) Connect the filter with full <i>Mitomycine Substipharm 20 mg</i> syringe to the intravenous catheter and push plunger to deliver filtered solution.</p> <p>or</p> <p>8) Connect the filter with full <i>Mitomycine Substipharm 20 mg</i> syringe to the luer-slip outlet of the infusion bag (if equipped) or and push plunger to deliver filtered solution or attach a needle to deliver the solution in the infusion bag by the septum.</p>